Department of Neurology, Drum Tower Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.
Department of Neurology, Nanjing Drum Tower Hospital, Nanjing, Jiangsu, PR China.
JPEN J Parenter Enteral Nutr. 2018 Jul;42(5):926-932. doi: 10.1002/jpen.1035. Epub 2017 Dec 18.
Glycemic control is essential for managing acute stroke. This study evaluated the impact of a diabetes-specific formula (DSF) on glycemic control in severe acute ischemic stroke patients.
A randomized, prospective controlled trial was conducted in Nanjing Drum Tower Hospital. Acute ischemic stroke patients who scored > 10 on the National Institutes of Health Stroke Scale as well as had swallowing problems were randomized to group A, which received a diabetes-specific enteral formula, and group B, which received a standard formula. Glycemic parameters were assessed at baseline and 7 days after admission.
One hundred four patients were enrolled in the study (group A, 53; group B, 51). Postprandial glucose parameters, including capillary glucose concentration from 8 hours to 16 hours after enteral nutrition (EN) consumption, incremental areas under the curve (iAUC ), peak value, and mean glucose concentration, were significantly lower in group A than in group B following a 7-day intervention period. Moreover, changes in HOMA after the 7-day treatment were significantly higher in group A than in group B. No significant difference in the incidence of hypoglycemia, glycemic variability parameters, or nutrition parameters was found between the 2 groups, either at baseline or after treatment. There were no serious adverse events observed during the study.
A diabetes-specific formula may improve acute-term glycemic control in severe acute ischemic stroke patients.
血糖控制对于急性脑卒中的管理至关重要。本研究评估了糖尿病专用配方(DSF)对重症急性缺血性脑卒中患者血糖控制的影响。
本研究在南京鼓楼医院进行了一项随机、前瞻性对照试验。入选 NIHSS 评分>10 分且存在吞咽问题的急性缺血性脑卒中患者,随机分为 A 组(接受糖尿病专用肠内配方)和 B 组(接受标准配方)。在入院时和入院后 7 天评估血糖参数。
本研究共纳入 104 例患者(A 组 53 例,B 组 51 例)。与 B 组相比,A 组患者在接受 7 天干预后,餐后血糖参数(包括肠内营养后 8 至 16 小时的毛细血管葡萄糖浓度、增量曲线下面积(iAUC)、峰值和平均葡萄糖浓度)显著降低。此外,A 组患者治疗 7 天后 HOMA 的变化明显高于 B 组。两组患者在基线或治疗后,在低血糖发生率、血糖变异性参数或营养参数方面均无显著差异。研究过程中未观察到严重不良事件。
糖尿病专用配方可能改善重症急性缺血性脑卒中患者的急性血糖控制。